The confirmation of the harmful effect of CCL5 in the acute phase of stroke is supported by the correlation observed between the biomarkers of inflammation, IL-6 and TNF-α [31,32], previously determined by our research centre, which is among the first to be released during ischemia in AIS (Figure 4). The gene discussed is CCL5; the disease is stroke disorder.